Business Description
![Savara Inc Savara Inc logo](https://static.gurufocus.com/logos/0C0000099S.png?14)
Savara Inc
NAICS : 325412
SIC : 2834
ISIN : US8051111016
Description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.39 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -0.38 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23.6 | |||||
3-Year EPS without NRI Growth Rate | 26.9 | |||||
3-Year FCF Growth Rate | 24.7 | |||||
3-Year Book Growth Rate | -5.1 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.19 | |||||
9-Day RSI | 68.13 | |||||
14-Day RSI | 63.97 | |||||
6-1 Month Momentum % | -4.23 | |||||
12-1 Month Momentum % | 32.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.9 | |||||
Quick Ratio | 14.9 | |||||
Cash Ratio | 14.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.6 | |||||
Shareholder Yield % | 0.11 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -54.21 | |||||
ROA % | -42.03 | |||||
ROIC % | -504.51 | |||||
ROC (Joel Greenblatt) % | -31436.26 | |||||
ROCE % | -47.83 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.64 | |||||
Price-to-Tangible-Book | 6.2 | |||||
EV-to-EBIT | -10.03 | |||||
EV-to-Forward-EBIT | -7.69 | |||||
EV-to-EBITDA | -10.06 | |||||
EV-to-FCF | -11.46 | |||||
Price-to-Net-Current-Asset-Value | 6.28 | |||||
Price-to-Net-Cash | 6.44 | |||||
Earnings Yield (Greenblatt) % | -9.97 | |||||
FCF Yield % | -7.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SVRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Savara Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.37 | ||
Beta | 0.62 | ||
Volatility % | 30.3 | ||
14-Day RSI | 63.97 | ||
14-Day ATR ($) | 0.283781 | ||
20-Day SMA ($) | 4.3125 | ||
12-1 Month Momentum % | 32.47 | ||
52-Week Range ($) | 3.111 - 5.7 | ||
Shares Outstanding (Mil) | 164.44 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Savara Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Savara Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Savara Inc Frequently Asked Questions
What is Savara Inc(SVRA)'s stock price today?
The current price of SVRA is $4.96. The 52 week high of SVRA is $5.70 and 52 week low is $3.11.
When is next earnings date of Savara Inc(SVRA)?
The next earnings date of Savara Inc(SVRA) is 2024-08-09 Est..
Does Savara Inc(SVRA) pay dividends? If so, how much?
Savara Inc(SVRA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |